Entera Bio Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Entera Bio Ltd., a foreign private issuer, covers the month of December 2019. The report, dated December 11, 2019, incorporates by reference a press release issued on the same date. The registrant is headquartered in Jerusalem, Israel, and files annual reports under Form 20-F.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a vehicle to distribute a press release and does not contain a financial statement or quantitative performance data within the provided text.
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period. No comparative financial data or specific operational changes are detailed in the provided excerpt.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The content is limited to the administrative details of the filing and the incorporation of an external press release exhibit.
Key Facts for Investor Verification
- The filing is a procedural Form 6-K incorporating a press release dated December 11, 2019.
- No financial metrics or operational results are disclosed in the provided text.
- Investors must review the attached Exhibit 99.1 (the press release) to understand the specific announcement triggering this filing.
- The company is led by CEO Adam Gridley, who signed the report.